The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers

Randomized, Open-label, Crossover Study to Evaluate the Effect of Genetic Polymorphism on Pharmacokinetic & Pharmacodynamic Interactions of Clopidogrel and Cilostazol in Korean Healthy Adult Volunteers

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01482117

Enrollment

Registered

2011-11-30

Start date

2011-11-30

Completion date

2012-02-29

Last updated

2013-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interaction

Keywords

CYP2C19, CYP3A5, Clopidogrel, Cilostazol, Healthy

Brief summary

The aim of this study is to investigate the effects of genetic polymorphisms on pharmacokinetic and pharmacodynamic interactions of clopidogrel and cilostazol in Korean healthy adult volunteers.

Interventions

DRUGClopidogrel

single oral administration of 300mg of clopidogrel

DRUGCilostazol

single oral administration of 100mg cilostazol

DRUGClopidogrel/Cilostazol

single oral administration of 300mg clopidogrel and 100mg cilostazol

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

20 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male subject whose CYP2C19 genotype was determined

Exclusion criteria

* Subject who has abnormal laboratory test results

Design outcomes

Primary

Measure	Time frame	Description
Maximum concentration(Cmax), Area under the concentration(AUC), Inhibition of platelet aggregation(IPA)	up to 24 hours	9 or 11 point blood sampling according to the interventions

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026